NeuroRestore
NeuroRestore is a Lausanne-based research center, jointly operated by EPFL, CHUV, and UNIL, that develops implantable neurotechnologies (brain-spine interfaces, epidural stimulation, neuroprosthetic systems) to restore neurological function in patients with spinal cord injury, Parkinson's, stroke, and traumatic brain injury.
- Company typePrivate
- Founded2019
- HeadquartersVaud, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What NeuroRestore does
NeuroRestore is a research, innovation, and treatment center headquartered in Lausanne, Switzerland, with an additional engineering presence at Campus Biotech in Geneva. Founded in December 2019, it is jointly operated by EPFL, the Lausanne University Hospital (CHUV), and the University of Lausanne (UNIL), with the Defitech Foundation as a founding financial supporter. The center is co-directed by neuroscientist Grégoire Courtine (EPFL) and neurosurgeon Jocelyne Bloch (CHUV) and employs a 70+ member multidisciplinary team of principal investigators, postdocs, PhD students, and clinical staff. Its mission is to develop and clinically translate implantable neurotechnologies that restore neurological function in patients with spinal cord injury, Parkinson's disease, stroke, and traumatic brain injuries. The portfolio spans the Brain-Spine Interface (wireless digital bridge), STIMO-BRIDGE activity-dependent epidural stimulation, Electronic Dura Mater (e-dura) soft implants, the Neuroprosthetic Baroreflex for hemodynamic control, Hypothalamic Deep Brain Stimulation, ARCEX non-invasive therapy, and the Tabulae Paralytica molecular atlases of spinal cord injury. AI/ML capabilities, including motor-intention decoding, closed-loop EMG/video optimization, and single-cell transcriptomic analysis via the Augur method, are embedded across the technology stack.
As a research center rather than a commercial entity, NeuroRestore is funded primarily through foundation grants (Defitech), institutional support from EPFL/CHUV/UNIL, and collaborative agreements. Pricing is not applicable. The go-to-market motion is event-driven: therapies are validated through clinical trials at CHUV and international partner hospitals (Netherlands, Canada, France), with commercialization of the brain-spine interface channeled exclusively through ONWARD Medical, a spin-off from EPFL, in partnership with CEA and supported by the European Innovation Council. Patient recruitment occurs via clinical trial waiting lists, and the center reaches the medical community through top-tier academic publications (Nature, Science, Nature Medicine), scientific conferences, and earned media. End beneficiaries are patients with paralysis, Parkinson's, stroke, and TBI; downstream commercial customers are rehabilitation clinics that will deploy approved therapies following regulatory clearance.
NeuroRestore firmographics
Firmographics- Name
- NeuroRestore
- Legal name
- NeuroRestore
- Website
- https://neurorestore.swiss
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NeuroRestore is a Lausanne-based research center, jointly operated by EPFL, CHUV, and UNIL, that develops implantable neurotechnologies (brain-spine interfaces, epidural stimulation, neuroprosthetic systems) to restore neurological function in patients with spinal cord injury, Parkinson's, stroke, and traumatic brain injury.
- Ownership category
- akta.pro rank
NeuroRestore industry classification
Industry- Product category
- Neurotechnology Research and Clinical Trials
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neural & Spinal Cord Regeneration (HLAAAGAI)
- akta.pro secondary industries
- Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s) (HLADAJAH), Neurorehabilitation Centers (HLAFAFAH)
Keywords
Where NeuroRestore is headquartered
LocationHeadquarters
- HQ city
- Vaud
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
NeuroRestore business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Research Grants and Foundation Funding: NeuroRestore operates as a research center funded by foundations (Defitech Foundation) and institutional support from EPFL, CHUV, and UNIL
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
NeuroRestore product offering
Product offeringCore offering
NeuroRestore is a research, innovation, and treatment center that develops and applies bioengineering strategies involving neurosurgical interventions to restore neurological functions. Its core offering comprises implantable neurotechnologies and clinical programs — including epidural spinal stimulation systems, brain-spine interfaces, neuroprosthetic baroreflex, and hypothalamic deep brain stimulation — validated through rigorous preclinical and clinical studies in patients with spinal cord injury, Parkinson's disease, stroke, and traumatic brain injuries.
Product overview
NeuroRestore is a research and innovation center spanning EPFL, CHUV, and UNIL that develops and applies medical therapies aimed at restoring neurological functions. The organization integrates implantable neurotechnologies with innovative treatments developed through rigorous preclinical and clinical studies. Their core technology portfolio includes the STIMO clinical program using targeted epidural spinal stimulation (TESS), the Brain-Spine Interface (digital bridge) for restoring natural movement control, ARCEX Therapy for non-invasive tetraplegia treatment, the Parkinson's Spinal Neuroprosthesis, the Neuroprosthetic Baroreflex for blood pressure control, and Hypothalamic Deep Brain Stimulation. These developments have led to breakthroughs for treating paraplegia, tetraplegia, Parkinson's disease, stroke, and traumatic brain injuries.
Differentiator
Problem solved
Functional benefit
Products and services
- Brain-Spine Interface (Digital Bridge) Wireless digital bridge between the brain and spinal cord that decodes cortical motor intentions and translates them into epidural spinal cord stimulation sequences, enabling paralyzed patients to walk, stand, and control movement naturally. Targeted at patients with chronic spinal cord injury participating in clinical trials.
- STIMO (STImulation Movement Overground) Clinical feasibility program delivering targeted epidural spinal stimulation (TESS) at specific locations synchronized with intended leg movements to restore motor functions in patients with chronic spinal cord injury.
- Parkinson's Spinal Neuroprosthesis Closed-loop spinal cord neuroprosthesis targeting dorsal root entry zones to reproduce natural spatiotemporal activation of lumbosacral spinal cord during walking, working synergistically with subthalamic nucleus deep brain stimulation to alleviate gait deficits, freezing of gait, and falls in patients with advanced Parkinson's disease.
- ARCEX Therapy Non-invasive spinal cord electrical stimulation therapy applied externally over the cervical spinal cord during structured rehabilitation sessions to improve arm and hand functions in people with chronic tetraplegia.
- Neuroprosthetic Baroreflex Implantable closed-loop system that uses biomimetic epidural electrical stimulation to restore hemodynamic stability, regulate blood pressure, and treat autonomic dysreflexia in patients with spinal cord injury.
- Hypothalamic Deep Brain Stimulation (DBSLH) Deep brain stimulation therapy targeting lateral hypothalamus neurons to augment walking recovery after incomplete spinal cord injury through reorganization of lumbar-terminating projections.
- Hemodynamic Stability System Implantable system that uses biomimetic epidural electrical stimulation targeting the last three thoracic spinal segments to regulate blood pressure, treat hypotensive complications, and safely manage autonomic dysreflexia in spinal cord injury patients.
- Rehabilitation Robotics Integration Combined therapy platform that integrates the implantable spinal cord neuroprosthesis with rehabilitation robotics for robot-assisted walking and cycling, enabling neurological improvements and outdoor recreational activities for spinal cord injury patients.
Quantifiable outcome
- 9 patients recovered walking ability with EES and neurorehabilitation, with improvements persisting even when stimulation was turned off
- +4 more outcomes
Companies that use NeuroRestore
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
NeuroRestore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature8 records
NeuroRestore partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Inserm and University of BordeauxminorCollaborated on development of spinal cord neuroprosthesis for Parkinson's disease gait deficits
- Wyss Center for Bio and NeuroengineeringminorWyss Center provides facilities and support, with Mark Anderson serving as scientist at the center while also directing CNS Regeneration at NeuroRestore
- UCLA and Harvard Medical SchoolminorCollaborated on single-cell nuclear RNA sequencing research to identify neuronal subpopulations involved in spinal cord repair
- CEA (French Alternative Energies and Atomic Energy Commission)coreCEA developed the WIMAGINE® brain recording devices and BCI algorithms, providing the brain-computer interface technology that decodes cortical signals for the brain-spine interface
- ONWARD MedicalcoreONWARD Medical is developing a commercial version of the brain-spine interface digital bridge technology in partnership with CEA and EPFL, with support from the European Innovation Council (EIC) to make the technology available worldwide
- Sint Maartenskliniek (Netherlands)minorInternational clinical collaborator for hemodynamic stability research after spinal cord injury
- Radboudumc (Netherlands)minorInternational clinical collaborator for spinal cord injury research
- University of Calgary (Canada)minorInternational collaborator from Canada contributing to hemodynamic research and autonomic dysreflexia studies
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
NeuroRestore competitors and assessment
Company assessmentEmerging players
- Paradromics: Paradromics develops high-data-rate implantable brain-computer interfaces targeting motor and communication restoration. It operates in the same intracortical BCI category as NeuroRestore's brain-spine interface for paralysis.
- Synchron: Synchron develops a minimally invasive endovascular brain-computer interface for paralysis patients, pursuing motor-restoration use cases that overlap with NeuroRestore's spinal cord stimulation work. It represents a less invasive alternative approach in adjacent BCI territory.
- InBrain Neuroelectronics: InBrain Neuroelectronics develops graphene-based neural interfaces for brain stimulation and recording in neurological disorders. It shares NeuroRestore's pursuit of novel electrode materials and neuromodulation therapies.
- Motif Neurotech: Motif Neurotech develops minimally invasive brain stimulation devices for mental health and neurological indications. While its lead focus differs, it represents an emerging peer in the implantable/wearable neurotechnology space adjacent to NeuroRestore's stimulation work.
- Blackrock Neurotech: Blackrock Neurotech builds implantable neural interfaces for motor and communication restoration in paralysis and other neurological conditions. It shares NeuroRestore's focus on intracortical recording and motor decoding for movement rehabilitation.
Others
- EPFL (École Polytechnique Fédérale de Lausanne): EPFL is NeuroRestore's founding academic institution and houses Grégoire Courtine's lab. It provides research infrastructure, engineering talent, and the broader neuroscience/engineering ecosystem that underpins NeuroRestore's work.
- Kessler Foundation: Kessler Foundation is a U.S. nonprofit conducting neurorehabilitation research for spinal cord injury, brain injury, and stroke. It pursues overlapping clinical translation goals in SCI motor recovery, providing a non-profit research center comparator.
- Wyss Center for Bio and Neuroengineering: The Wyss Center is a Geneva-based neurotechnology translational research facility that collaborates directly with NeuroRestore (Mark Anderson holds dual roles). It provides infrastructure and engineering support for similar neural interface and rehabilitation projects.
Direct peers
- ONWARD Medical: ONWARD Medical is an EPFL spin-off commercializing epidural electrical stimulation therapies for spinal cord injury, including technology developed with Courtine and Bloch. It is NeuroRestore's designated commercialization partner and pursues overlapping SCI restoration indications.
Broad incumbents
- Neuralink: Neuralink develops high-bandwidth implantable brain-computer interfaces aimed at restoring motor and sensory function in paralysis. While broader in ambition and much better capitalized, it competes in the same motor-restoration BCI space as NeuroRestore's brain-spine interface.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
NeuroRestore social profiles
Digital presenceNeuroRestore financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroRestore leadership team
Management profileNumber of profiles
Profiles3 records
NeuroRestore funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroRestore M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroRestore
What does NeuroRestore do?
NeuroRestore is a research, innovation, and treatment center that develops and applies bioengineering strategies involving neurosurgical interventions to restore neurological functions. Its core offering comprises implantable neurotechnologies and clinical programs — including epidural spinal stimulation systems, brain-spine interfaces, neuroprosthetic baroreflex, and hypothalamic deep brain stimulation — validated through rigorous preclinical and clinical studies in patients with spinal cord injury, Parkinson's disease, stroke, and traumatic brain injuries.
Is NeuroRestore a public or private company?
NeuroRestore is a private company. It is classified as unknown and is currently operating.
When was NeuroRestore founded?
NeuroRestore was founded in 2019. It employs 101 to 250 people.
Where is NeuroRestore based?
NeuroRestore is headquartered in Vaud, Switzerland, in the Europe region.
How does NeuroRestore make money?
One revenue line is on record: research Grants and Foundation Funding.
Who are NeuroRestore's main competitors?
Emerging players on record are Paradromics, Synchron, InBrain Neuroelectronics, Motif Neurotech and Blackrock Neurotech. Others are EPFL (École Polytechnique Fédérale de Lausanne), Kessler Foundation and Wyss Center for Bio and Neuroengineering. ONWARD Medical is listed as a direct peer. Neuralink is listed as a broad incumbent.
Does NeuroRestore have an API?
No public API is recorded for NeuroRestore.
What industry is NeuroRestore in?
NeuroRestore's product category is Neurotechnology Research and Clinical Trials. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLADAJAH, Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s). Its NAICS code is 334510 and its SIC code is 3845.